49 results
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
9 May 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
6:37am
, cash equivalents and marketable securities to be sufficient to fund its current operating plan into 2027.
R&D Expenses: Research and development (R&D … and presentations; Nuvalent's research and development programs for the treatment of cancer; and risks and uncertainties associated with drug
8-K
EX-99.1
NUVL
Nuvalent Inc - Ordinary Shares
27 Feb 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
6:38am
to be sufficient to fund its current operating plan into 2027.
R&D Expenses: Research and development (R&D) expenses were $35.6 million … with regulators and investigators; the design and timing of the planned Phase 2 portion of the ARROS-1 and ALKOVE-1 trials; Nuvalent's research and development
8-K
EX-99.1
0kceexugm ig
9 Jan 24
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
4:40pm
8-K
EX-99.1
jcy5t vcr
14 Nov 23
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter
6:45am
424B5
o5oy04sfqn0odtv
17 Oct 23
Prospectus supplement for primary offering
4:05pm
424B5
pzdkofpv15l3tb1sa4o
16 Oct 23
Prospectus supplement for primary offering
7:39am
8-K
0gw30c4
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
pexmqhp 4b6
13 Oct 23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial
6:40am
8-K
EX-99.1
1hp7o9d oyg2w
4 Oct 23
Other Events
4:05pm
8-K
8zr dsh2rr8ef3
4 Oct 23
Other Events
4:05pm
8-K
EX-99.1
zlxdidicj78d5pf efo
10 Aug 23
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
6:45am
8-K
EX-99.1
bq4qi awdntzd6e
11 May 23
Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results
6:39am
PRE 14A
bav9t2wf ufg
13 Apr 23
Preliminary proxy
4:30pm